Schwab Charles Investment Management Inc. boosted its position in Edwards Lifesciences Corporation (NYSE:EW) by 5.5% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 695,011 shares of the medical research company’s stock after purchasing an additional 36,423 shares during the period. Schwab Charles Investment Management Inc. owned about 0.33% of Edwards Lifesciences worth $75,972,000 as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in EW. Bank of New York Mellon Corp raised its stake in shares of Edwards Lifesciences by 161.7% in the second quarter. Bank of New York Mellon Corp now owns 5,304,536 shares of the medical research company’s stock worth $627,207,000 after buying an additional 3,277,726 shares during the period. Egerton Capital UK LLP bought a new position in shares of Edwards Lifesciences in the second quarter worth about $217,805,000. Koch Industries Inc. raised its stake in shares of Edwards Lifesciences by 28,363.1% in the second quarter. Koch Industries Inc. now owns 1,397,254 shares of the medical research company’s stock worth $1,386,000 after buying an additional 1,392,345 shares during the period. Artisan Partners Limited Partnership raised its stake in Edwards Lifesciences by 90.6% during the 2nd quarter. Artisan Partners Limited Partnership now owns 1,278,532 shares of the medical research company’s stock valued at $151,174,000 after purchasing an additional 607,784 shares during the period. Finally, Old Mutual Global Investors UK Ltd. raised its stake in Edwards Lifesciences by 83.0% during the 3rd quarter. Old Mutual Global Investors UK Ltd. now owns 1,100,885 shares of the medical research company’s stock valued at $120,337,000 after purchasing an additional 499,436 shares during the period. 81.55% of the stock is currently owned by institutional investors and hedge funds.
Several analysts recently issued reports on EW shares. Canaccord Genuity reissued a “buy” rating and set a $135.00 target price (down previously from $155.00) on shares of Edwards Lifesciences in a research note on Wednesday, October 25th. BMO Capital Markets reissued a “buy” rating and set a $132.00 target price on shares of Edwards Lifesciences in a research note on Friday, September 1st. William Blair reissued an “outperform” rating on shares of Edwards Lifesciences in a research note on Monday, August 28th. SunTrust Banks set a $124.00 target price on Edwards Lifesciences and gave the company a “buy” rating in a research note on Wednesday, October 25th. Finally, Morgan Stanley decreased their target price on Edwards Lifesciences from $133.00 to $120.00 and set an “overweight” rating on the stock in a research note on Thursday, October 26th. Seven research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $125.53.
Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, October 24th. The medical research company reported $0.84 EPS for the quarter, missing the Zacks’ consensus estimate of $0.86 by ($0.02). The company had revenue of $821.50 million during the quarter, compared to analysts’ expectations of $833.85 million. Edwards Lifesciences had a return on equity of 27.22% and a net margin of 22.47%. Edwards Lifesciences’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same quarter last year, the firm posted $0.68 EPS. sell-side analysts expect that Edwards Lifesciences Corporation will post 3.75 earnings per share for the current year.
In other news, CEO Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $100.93, for a total value of $3,320,597.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, November 29th. The stock was sold at an average price of $116.45, for a total value of $617,185.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 172,480 shares of company stock valued at $18,548,810. Company insiders own 2.13% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Schwab Charles Investment Management Inc. Increases Holdings in Edwards Lifesciences Corporation (EW)” was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/12/03/schwab-charles-investment-management-inc-increases-holdings-in-edwards-lifesciences-corporation-ew.html.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).
What are top analysts saying about Edwards Lifesciences Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Edwards Lifesciences Corporation and related companies.